Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Paracentesis Stories

2013-01-21 08:24:55

KING OF PRUSSIA, Pa., Jan. 21, 2013 /PRNewswire/ -- Treatment with albumin reduces renal impairment and mortality in cirrhotic patients with spontaneous bacterial peritonitis (SBP), one of the most common bacterial infections in this patient population, according to a new meta-analysis supported by CSL Behring and published today in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association Institute. Albumin, a natural...

2012-10-30 07:26:44

ZÃœRICH, Switzerland, October 30, 2012 /PRNewswire/ -- Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump(R) system in patients with ascites caused by cancer (malignant ascites). The alfapump(R) system was first introduced to the European market last year for patients with refractory ascites caused by advanced liver disease. The system is fully implantable, and automatically and continually collects ascites from the...

2012-03-28 10:22:59

KING OF PRUSSIA, Pa., March 28, 2012 /PRNewswire/ -- Administration of albumin reduces morbidity and mortality in cirrhotic patients undergoing large-volume paracentesis due to severe ascites, according to a new meta-analysis published online today in Hepatology, the official journal of the American Association for the Study of Liver Diseases. Compared with alternative treatments, albumin, a natural plasma-derived protein that expands blood plasma volume, significantly reduced the circulatory...

2012-03-01 00:00:00

ZÃœRICH, March 1, 2012 /PRNewswire/ -- NUB Grants Approval for Fifteen Leading Hepatology Centres in Germany. Sequana Medical announced today that its ALFApump(R) System has received German Neue Untersuchungs und Behandlungsmethode (NUB) approval which allows participating hospitals to receive reimbursement for innovative new products. Sequana Medical's ALFApump System is a fully implantable pump system designed to remove excess abdominal fluid, known as...

2011-12-09 00:00:00

ZURICH, December 9, 2011 /PRNewswire/ -- NHS National Innovation Centre supports the cost effectiveness of Sequana Medical's ALFApump System Sequana Medical announced today the findings of an independent economic assessment of the ALFApump System commissioned by the National Innovation Centre, the NHS organization which supports innovators, commissioners, and clinicians to speed up the development and use of innovations that will benefit the NHS. Brian Winn, Head...

2011-11-04 05:38:00

ZURICH, Switzerland, November 4, 2011 /PRNewswire/ -- Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis. Sequana Medical, the Medical University of Vienna and Vienna General Hospital (AKH Wien) reported that the first two commercial implants worldwide of the ALFApump System were performed at Vienna General Hospital in October, under the supervision of Univ. Prof. Dr. Markus...

2011-07-13 00:00:00

ZURICH, Switzerland, July 13, 2011 /PRNewswire/ -- New Technology Expands Treatment Options for Patient With Refractory Ascites Due to Liver Cirrhosis. Dr. Farzana Malik Joins as Vice President of Market Access and Reimbursement. Sequana Medical announced today that it has received CE Mark approval for the commercial sale of its ALFApump(TM) System. Over the coming months, the company will launch the product in selected hepatology and liver transplant hospitals across...

2011-03-09 05:32:00

ZUG, Switzerland, March 9, 2011 /PRNewswire/ -- NovaShunt AG, a private Swiss medical device company with innovative fluid management technologies, announced today that it has raised CHF 23.7 million (about $25 million) in a Series B preferred share financing round co-led by BioMedInvest AG, Entrepreneurs Fund and Capricorn Health-tech Fund. Existing investors, NeoMed and VI Partners, were also significant participants in the new financing and NeoMed retains its role as the lead investor...

2010-02-11 04:40:00

ZUG, Switzerland/>, February 11/> /PRNewswire/ -- NovaShunt today announced the initiation of its pivotal multi- center clinical study named PIONEER, a Prospective, multi-center, open label, non-randomized study to Investigate the safety and perfOrmance of the Automated Fluid ShuNt in patiEnts with ascitEs and diuretic Resistance. The study is designed to evaluate the safety and performance of the Automated Fluid Shunt (AFS) System in replacing the need for paracentesis, the standard...